Auvelity is the first non-antipsychotic FDA approval for Alzheimer's agitation. The Black-dementia question is whether the underdiagnosis pattern in US Medicare data suppresses access to the new on-label option.
On April 30, 2026 the FDA approved Auvelity (dextromethorphan with bupropion) for agitation associated with Alzheimer's disease, the first non-antipsychotic on-label option for an indication that had relied on off-label antipsychotics for 30 years. Three …
Black Health Editorial team
9 min read
